摘要
隐球菌是致病率及致死率均排在首位的人类致病真菌,主要感染严重免疫功能低下的患者,隐球菌感染病例逐年增多,在真菌性疾病当中位居首位。目前用于隐球菌治疗的抗真菌药局限于唑类、两性霉素B和5-氟胞嘧啶,疗程长且停药指标缺乏,导致停药后重复感染,并且二次用药后加快耐药隐球菌的产生,同时临床上也分离出越来越多的耐药菌株,然而目前对于隐球菌耐药机制的研究比较缺乏,在面临可能的大规模的耐药隐球菌的出现是个隐患。本文总结近年来关于隐球菌耐药菌株临床报道和耐药机制的研究,探讨下一步隐球菌的耐药机制的研究方向和用于治疗隐球菌感染的药物。
Cryptococcus is a human pathogenic fungus with the highest morbidity and mortality.Cryptococcus mainly infects patients with immunodeficiency.Cryptococcal infection has been increasing year by year,ranking first among fungal diseases.The antifungal drugs to cryptococcus are limited to azoles,amphotericin B and 5-fluorocytosine.Because of long-course treatment and the lack of biomarkers for indicating to stop treatment,patients suffer from repeating infection after stopping the drug by cryptococcus with high-possible drug resistance.More and more clinical drug-resistant strains have been isolated,however there is little systematic research on the mechanisms of drug resistance in cryptococcus,which is a potential risk in the face of emergence of drug-resistant cryptococcus.This review mainly summarized the research in the clinical reports and drug resistance mechanisms of cryptococcal drug-resistant strains in recent years,and discussed the future research directions of the resistance mechanisms of cryptococcus and potential anti-cryptococcus drugs.
作者
罗海海
卢才菊
张伟
徐新平
LUO Hai-hai;LU Cai-ju;ZHANG Wei;XU Xin-ping(Nanchang University,Nanchang 330006,China;The First Affiliated Hospital of Nanchang University,Nanchang 330006,China;The First Affiliated Hospital of Nanchang University,Jiangxi Institute of Respiratory Disease,Nanchang 330006,China)
出处
《中国人兽共患病学报》
CAS
CSCD
北大核心
2020年第9期763-771,共9页
Chinese Journal of Zoonoses
基金
国家自然科学基金(No.13009083)。
关键词
隐球菌
耐药菌
耐药机制
抗菌药物
Cryptococcus
drug-resistant strains
resistance mechanisms
antifungal drugs
